Format

Send to

Choose Destination
Commun Biol. 2019 May 29;2:200. doi: 10.1038/s42003-019-0455-x. eCollection 2019.

Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma.

Author information

1
1Department of Biology, Boston College, Chestnut Hill, MA 02467 USA.
2
BERG LLC, Framingham, MA 01701 USA.
3
3Mass Spectrometry Center, Chemistry Department, Boston College, Chestnut Hill, 02467 USA.
4
4Rodent Pathology Core, Harvard Medical School, Boston, MA 02215 USA.
5
5Facultad de Medicina, Instituto de Investigaciones Biológicas, Universidad del Zulia, 526 Maracaibo, Venezuela.
6
6Department of Medical Biochemistry, Semmelweis University, Budapest, 1094 Hungary.

Abstract

Glioblastoma (GBM) is an aggressive primary human brain tumour that has resisted effective therapy for decades. Although glucose and glutamine are the major fuels that drive GBM growth and invasion, few studies have targeted these fuels for therapeutic management. The glutamine antagonist, 6-diazo-5-oxo-L-norleucine (DON), was administered together with a calorically restricted ketogenic diet (KD-R) to treat late-stage orthotopic growth in two syngeneic GBM mouse models: VM-M3 and CT-2A. DON targets glutaminolysis, while the KD-R reduces glucose and, simultaneously, elevates neuroprotective and non-fermentable ketone bodies. The diet/drug therapeutic strategy killed tumour cells while reversing disease symptoms, and improving overall mouse survival. The therapeutic strategy also reduces edema, hemorrhage, and inflammation. Moreover, the KD-R diet facilitated DON delivery to the brain and allowed a lower dosage to achieve therapeutic effect. The findings support the importance of glucose and glutamine in driving GBM growth and provide a therapeutic strategy for non-toxic metabolic management.

KEYWORDS:

CNS cancer; Cancer metabolism

Conflict of interest statement

Competing interestsThe authors declare no competing interests.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center